The Injected Plasma of Myasthenia Gravis Patient with A Low T-reg Level Caused Clinical Myasthenic Syndromes in Swiss-Webster Mice
Abstract
BACKGROUND: Myasthenia gravis (MG) is a rare autoimmune disease affecting neuromuscular junction involvement. The finding that T-reg level in MG patients was lower than that in normal persons leads to the idea that the primary pathology of the disease is T-reg dependent. The T-reg level of MG patients seems to be decreasing compared to that of normal persons. The study was conducted to observe the contribution of T-reg level in plasma injected into Swiss-Webster mice to develop clinically and pathologically myasthenic syndromes.
METHODS: Swiss-Webster mice were grouped into three groups: the groups received plasma with normal, low, and high T-reg levels, respectively. The T-reg levels of the mice were measured with flow cytometry analysis and a human regulatory T-cell cocktail for T-cell surface cell marker. The motor function, interleukin (IL)-2, interferon (IFN)-γ, and thymus weight of mice were measured after the injection. Histopathological examination was performed to analyze mice’s muscles and thymus.
RESULTS: The result identified that the motor function (2-week treatment group: p=0.021 and 3-week treatment group: p=0.032) and muscle width (p=0.014, p=0.032 and p≤0.001) were significantly lower in the low T-reg level plasma group compared to control and high T-reg level plasma groups. The thymus showed an increase in weight without an increase in the cortex-medulla ratio of the thymus, indicating hyperplasia. Both IL-2 and IFN-γ levels were lower in the low and high T-reg level groups compared with the control group, indicating the autoimmune process.
CONCLUSION: Low T-reg level was associated with lower motor function, muscle width, increased thymus weight, as well as lower IL-2 and IFN-γ levels. T-reg level contributed to clinical myasthenic syndromes but not pathological findings. This research method is expected to be a basis for the development of animal models with Swiss-Webster mice.
KEYWORDS: animal model, Myasthenia gravis, Swiss-Webster mice
Full Text:
PDFReferences
Gilhus NE, Owe JF, Hoff JM, Romi F, Skeie GO, Aarli JA. Myasthenia gravis: A review of available treatment approaches. Autoimmune Dis. 2011; 2011: 847393, CrossRef.
Tandon K. Myasthenia Gravis: Clinical and Immunological Aspects. Immunopathogenesis and Immune-based Therapy for Selected Autoimmune Disorders. London: InTech; 2017, CrossRef.
Kaminski HJ, Kusner LL. Myasthenia Gravis and Related Disorder. 3rd ed. Tarsy D, editor. Switzerland: Springer Nature; 2018, CrossRef.
Melzer N, Ruck T, Fuhr P, Gold R, Hohlfeld R, Marx A, et al. Clinical features, pathogenesis, and treatment of Myasthenia gravis: A supplement to the Guidelines of the German Neurological Society. J Neurol. 2016; 263(8): 1473-94, CrossRef.
Tjahjono Y, Caroline, Nugraha J, Foe K, Karnati S, Ergün S, et al. 2-(3-(chloromethyl)benzoyloxy)benzoic acid increases CD4+ regulatory T-cell population and foxP3 expression in lipopolysaccharide-induced mice. Indones Biomed J. 2023; 15(4): 339-46, CrossRef.
Fattorossi A, Battaglia A, Buzzonetti A, Ciaraffa F, Scambia G, Evoli A. Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: Effect of immunosuppressive treatment. Immunology. 2005; 116(1): 134-41, CrossRef.
Aricha R, Feferman T, Fuchs S, Souroujon MC. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol. 2008; 180(4): 2132-9, CrossRef.
Truffault F, Nazzal D, Verdier J, Gradolatto A, Fadel E, Roussin R, et al. Comparative analysis of thymic and blood treg in myasthenia gravis: thymic epithelial cells contribute to thymic immunoregulatory defects. Front Immunol. 2020; 11: 782, CrossRef.
Krisnamurti DGB, Hakim RW, Antarianto RD, Farida S, Purwaningsih EH, Purba JS. The role of Acalypha indica Linn. extract on heart rates with myasthenia gravis rat model. Asian J Pharm Clin Res. 2018; 11(1): 257-60, CrossRef.
Mantegazza R, Cordiglieri C, Consonni A, Baggi F. Animal models of myasthenia gravis: utility and limitations. Int J Gen Med. 2016; 9: 53-64, CrossRef.
Mathew J, Sankar P, Varacallo M. Physiology, Blood Plasma. In: StatPearls. Treasure Island: StatPearls Publishing; 2024, PMID.
Xu K, Shu XQ, Zhuo XL, Lu CZ. Presynaptic changes of neuromuscular transmission in mice induced by passive transfer of plasma with anti-presynaptic membrane receptor antibodies from a patient with myasthenia gravis. J Peripher Nerv Syst. 1998; 3(2): 103-9, PMID.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28(2): 193-213, CrossRef.
Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch Intern Med. 2006; 166(10): 1092-7, CrossRef.
Wang H, Li L, Zhang Y, Pan SC, Chen AQ, and Qian WD. Expression and significance of CD4+CD25+CD127- regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barré syndrome. Int J Clin Exp Med. 2015; 8(10): 19126-31, PMID.
Olivan S, Calvo AC, Rando A, Munoz MJ, Zaragoza P, and Osta R. Comparative study of behavioural tests in the SOD1G93A mice model of amyotrophic lateral sclerosis. Exp Anim. 2015; 64(2): 147-53, CrossRef.
Wijaya YH, Mahati E, Karlowee V, Istiadi H, Saraswati I, Najatullah, et al. The effect of Apium graveolens linn extract on the number of neutrophils and angiogenesis in wound incision of Sprague-Dawley rat. Azerbaijan Med J. 2023; 63(1): 6347-53, CrossRef.
Elmore SA. Enhanced histopathology of the thymus. Toxicol Pathol. 2006; 34(5): 656-65, CrossRef.
Rajendeeran A, Tenbrock K. Regulatory T cell function in autoimmune disease. J Transl Autoimmun. 2021; 4: 100130, CrossRef.
Zubidi N, McPherson K, Lee AG. Myasthenia gravis, overview. In: Schmidt-Erfurth U, Williams GA, Mieler W. Encyclopedia of Ophthalmology. New York: Springer; 2015. p.1-5, CrossRef.
Huang YM, Pirskanen R, Giscombe R, Linky H, Lefvert AK. Circulating CD4þCD25þ and CD4+CD25- T cells in myasthenia gravis and in relation to thymectomy. Scand J Immunol. 2004; 59(4): 408-14, CrossRef.
Nishimura T, Inaba Y, Nakazawa Y, Omata T, Akasaka M, Shirai I, et al. Reduction in peripheral regulatory T cell population in childhood ocular type myasthenia gravis. Brain Dev. 2015; 37(8): 808-16, CrossRef.
Meiliana A, Dewi NM, Wijaya A. Molecular regulation and rejuvenation of muscle stem (satellite) cell aging. Indones Biomed J. 2015; 7(2): 73-86, CrossRef.
Rudolf R, Deschenes MR, Sandri M. Neuromuscular junction degeneration in muscle wasting. Curr Opin Clin Nutr Metab Care. 2016; 19(3): 177-81, CrossRef.
Hajibehzad MA, Kasapoglu P, Jafari R, Rezaei N. The role of T regulatory cells in immunopathogenesis of myasthenia gravis. Expert Rev Clin Immunol. 2015; 11(7): 859-70, CrossRef.
Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W, Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: Correlation to disease activity. Rheumatol Int. 2012; 32(3): 639-43, CrossRef.
Rollings CM, Sinclair LV, Brady HJM, Cantrell DA, Ross SH. Interleukin-2 shapes the cytotoxic T cell proteome and immune environment-sensing programs. Sci Signal. 2018; 11(526): eaap8112, CrossRef.
Zorn E, Nelson EA, Mohseni M, Porchera F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006; 108(5): 1571-9, CrossRef.
Dwiningsih F, Natzir R, Ilhamuddin, Yustisia I, Sulfahri. Andrographis paniculata leaf extract increases interleukin-2 in malnutrition rat mode. Indones Biomed J. 2024; 16(3): 218-27, CrossRef.
Cohen-Kaminsky S, Jacques Y, Aime C, Safar D, Morel E, Berrih-Aknin S. Follow-up of soluble interleukin-2 receptor levels after thymectomy in patients with myasthenia gravis. Clin Immunol Immunopathol. 1992; 62(2): 190-8, CrossRef.
Isakson SH, Katzman SD, Hoyer KK. Spontaneous autoimmunity in the absence of il-2 is driven by uncontrolled dendritic cells. J Immunol. 2012; 189(4): 1585-93, CrossRef.
Huang J, Zhang T, Wang H, and Zhao Y. Treatment of experimental autoimmune myasthenia gravis rats with FTY720 and its effect on Th1/Th2 cells. Mol Med Rep. 2018; 17(5): 7409-14, CrossRef.
Huan X, Zhao R, Song J, Zhong H, Su M, Yan C, et al. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunol. 2022; 23: 26, CrossRef.
Payet CA, You A, Fayet OM, Dragin N, Berrih-Aknin S, Le Panse R. Myasthenia gravis: An acquired interferonopathy? Cells. 2022; 11(7): 1218, CrossRef.
Lopes N, Serge A, Ferrier P, Irla M. Thymic crosstalk coordinates medulla organization and t-cell tolerance induction. Front Immunol. 2015; 6: 365, CrossRef.
Thapa P, Farber DL. The role of the thymus in the immune response. Thorac Surg Clin. 2019; 29(2): 123-31, CrossRef.
Millington KA, Innes JA, Hackforth S, Hinks TSC, Deeks JJ, Dosanjh DPS, et al. Dynamic relationship between IFN-γ and IL-2 profile of Mycobacterium tuberculosis-specific T cells and antigen load. J Immunol. 2007; 178(8): 5217-26, CrossRef.
Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol. 2000; 94(2): 75-87, CrossRef.
Balasa B, Deng C, Lee J, Bradley LM, Dalton DK, Christadoss P, et al. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med. 1997; 186(3): 385-91, CrossRef.
Ulusoy C, Çavuş F, Yılmaz V, Tüzün E. Immunization with recombinantly expressed LRP4 induces experimental autoimmune myasthenia gravis in C57BL/6 Mice. Immunol Invest. 2017; 46(5): 490-9, CrossRef.
DOI: https://doi.org/10.18585/inabj.v16i4.3086
Copyright (c) 2024 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute